arrow
A

Ainhoa Hernández

Institut Català d'Oncologia
H指数:11
被引数:588

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Progression-Free Survival 2 as a Potential Surrogate for Overall Survival in Glioblastoma: Insights From a Spanish Multicentric Cohort

无进展生存期2作为胶质母细胞瘤总生存期的潜在替代指标:来自西班牙多中心队列的见解

2026-04-190
OAAI
PRIMARY RESULTS OF THE RANDOMIZED CLINICAL TRIAL OF BERUBICIN VS LOMUSTINE IN PATIENTS WITH GLIOBLASTOMA AFTER FAILURE OF PRIMARY THERAPY: DATA ANALYSIS AND FUTURE POSSIBILITIES

随机临床试验的初步结果:在初次治疗失败后的胶质母细胞瘤患者中比较鲁比西丁与洛莫司汀:数据分析与未来可能性

2025-11-010
OAAI
First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study
2024-12-170
OAAI
Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry
2024-10-010
OAAI
Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C

用免疫疗法治疗的具有KRAS突变的转移性肺癌患者队列的特征: 根据KRAS G12C与non-G12C的差异

2023-10-174
OAAI
Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker
CELLS
IF5.2
2023-03-081
OAAI
Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS-CoV-2 mRNA-1237 vaccine in patients with solid tumors

化疗和/或免疫治疗对实体瘤患者SARS-CoV-2 mRNA-1237疫苗中和抗体反应的影响

2022-12-305
OA
In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma
2022-08-243
OAAI
Immune response after vaccination against SARS-COV-2 in lung cancer (LC) patients (p). Prospective study in the Medical Oncology Department at the Catalan Institute of Oncology-Badalona, Spain: COVID-lung vaccine
2021-09-010
OAAI
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

使用真实数据的长期晚期 (iiib-iv) EGFR突变的非小细胞肺癌 (NSCLC) 幸存者的预后模型

2021-08-318
OAAI
Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
2020-12-1510
OAAI